Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The data are also summarized in Table 1.Clinical characteristics, fracture history, BMD scores at the time of first evaluation from the index patients of five families with a pathogenic variant in the gene encoding plastin-3 (PLS3)Index patientPLS3 mutationInheritance patternAge at first fracture (years)Height/BMI (z-score, SD)Long bone fratures (n)VCFsLaboratory and other evaluationsBMD before therapy (z-score, SD)BMD after therapy (z-score, SD)Other clinical findingsFamily 1Hemizygous frameshift variant c.1543del (p.Asp515Metfs*11)XL2 + 2/+ 18 (Ulna, radius, humerus, tibia, and metacarpals)T5C3: C5Dental examination noted poor trabecular bone in the jaw bone, but was otherwise normalGeneral endocrine/metabolic laboratory and ophthalmology assessments have been unremarkableLS − 1.6 (0.538 g/cm2)Total body less head − 0.9 (0.548 g/cm2)?(Pamidronate)Pectus excavatum, flat feet, broad and short thumbs and digit 4 to 5 syndactylyFamily 2Hemizygous nonsense variant c.827G>A (pTrp276*)XL13 − 2/− O.52 (radius)L1Full laboratory investigations were unremarkableLS − 3.7 (0.748 g/cm2)FN − 2.9 (0.665 g/cm2)TH − 3.0 (0.678 g/cm2)Radius ultradistal − 5.0 (0.274 g/cm2)FN − 2.8 (0.681 g/cm2)TH − 2.7 (0.706 g/cm2) (10 months teriparatide)LS − 4.9 (0.612 g/cm2) (15 months teriparatide): Family 3Hemizygous nonsense variant c.994_995delGA (p.Asp332*)De novo variant5 − 1/− 12 (Tibia, femur)Multiple vertebral bodiesLaboratory parameters of bone metabolism were repeatedly within age-appropriate normsLS − 2.9LS − 2.6 (4 months pamidronate)Pectus carinatum, Growth hormone deficiencyFamily 4Hemizygous deletion X:114771600-114890428XL1.5 − 1/− 27 (Forearm, wrist, elbow, and clavicle)L2Increased alkaline phosphatase and slightly increased PTH (67 ng/l; normal 15 to 65 ng/l) with vitamin D deficiency (18.4 μg/l; normal 30 to 70 μg/l)LS − 3LS − 2.67 (2 years pamidronate)Pectus carinatum, joint hypermobilityFamily 5Hemizygous deletion X:114644041-115418576XL80/+ 20From C7 to L5, it spares D1, D2, D10, and L1Bone resorption marker type 1 collagen N telopeptides in 24-h urine were greatly increased (1194 nM BCE/mM creatinine).
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
PLS3 Mutations in X-Linked Osteoporosis: Clinical and Genetic Features in Five New Families
Study design awaiting verification · Calcified Tissue International · 2023
Original publication title
PLS3 Mutations in X-Linked Osteoporosis: Clinical and Genetic Features in Five New Families
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Childhood-onset osteoporosis is a rare but clinically significant condition. Studies have shown pathogenic variants in more than 20 different genes as causative for childhood-onset primary osteoporosis. The X-chromosomal PLS3, encoding Plastin-3, is one of the more recently identified genes. In this study, we describe five new families from four different European countries with PLS3-related skeletal fragility. The index cases were all hemizygous males presenting with long bone and vertebral body compression fractures. All patients had low lumbar spine bone mineral density (BMD).
The age at the first clinical fracture ranged from 1.5 to 13 years old. Three of the identified PLS3 variants were stop-gain variants and two were deletions involving either a part or all exons of the gene. In four families the variant was inherited from the mother. All heterozygous women reported here had normal BMD and no bone fractures. Four patients received bisphosphonate treatment with good results, showing a lumbar spine BMD increment and vertebral body reshaping after 10 months to 2 years of treatment.
Our findings expand the genetic spectrum of PLS3-related osteoporosis. Our report also shows that early treatment with bisphosphonates may influence the disease course and reduce the progression of osteoporosis, highlighting the importance of early diagnosis for prompt intervention and appropriate genetic counseling.
Authors’ abstract
Childhood-onset osteoporosis is a rare but clinically significant condition. Studies have shown pathogenic variants in more than 20 different genes as causative for childhood-onset primary osteoporosis. The X-chromosomal PLS3, encoding Plastin-3, is one of the more recently identified genes. In this study, we describe five new families from four different European countries with PLS3-related skeletal fragility. The index cases were all hemizygous males presenting with long bone and vertebral body compression fractures. All patients had low lumbar spine bone mineral density (BMD).
The age at the first clinical fracture ranged from 1.5 to 13 years old. Three of the identified PLS3 variants were stop-gain variants and two were deletions involving either a part or all exons of the gene. In four families the variant was inherited from the mother. All heterozygous women reported here had normal BMD and no bone fractures. Four patients received bisphosphonate treatment with good results, showing a lumbar spine BMD increment and vertebral body reshaping after 10 months to 2 years of treatment.
Our findings expand the genetic spectrum of PLS3-related osteoporosis. Our report also shows that early treatment with bisphosphonates may influence the disease course and reduce the progression of osteoporosis, highlighting the importance of early diagnosis for prompt intervention and appropriate genetic counseling.
Publication and source details
Original title: PLS3 Mutations in X-Linked Osteoporosis: Clinical and Genetic Features in Five New Families
Adriana Costa; Andreia Martins; Catarina Machado; Elena Lundberg; Ola Nilsson; Fan Wang; Alice Costantini; Symeon Tournis; Jakob Höppner; Corinna Grasemann; Outi Mäkitie
Calcified Tissue International · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.ESPE Research Unit Grant, the Academy of Finlandhttp://dx.doi.org/10.13039/501100004359Vetenskapsrådethttp://dx.doi.org/10.13039/501100006129Konung Gustaf V:s och Drottning Victorias Frimurarestiftelsehttp://dx.doi.org/10.13039/501100006306Sigrid Juséliuksen SäätiöHospital Amadora-Sintra, S.A. (Hospital Professor Doutor Fernando Fonseca)Open access funding provided by FCT|FCCN (b-on).
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T14:32:08.054594+00:00
DOI: 10.1007/s00223-023-01162-4 · PMC10803541